Disc Medicine Announces Presentation of New Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2024 American Society of Nephrology (ASN) Kidney Week
11. Oktober 2024 08:00 ET
|
Disc Medicine Inc
WATERTOWN, Mass., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of...
Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Steve Caffé, MD as Chief Regulatory Officer
19. September 2024 08:30 ET
|
Disc Medicine Inc
WATERTOWN, Mass., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of...
Disc Medicine to Participate in Upcoming Investor Conferences
30. August 2024 08:00 ET
|
Disc Medicine Inc
WATERTOWN, Mass., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of...
Disc Medicine Reports Second Quarter 2024 Financial Results and Provides Business Update
08. August 2024 08:00 ET
|
Disc Medicine Inc
Presented positive data for all three programs at the European Hematology Association (EHA) 2024 Congress; demonstrated potential efficacy for bitopertin in erythropoietic protoporphyria (EPP) and...
Disc Medicine Announces Underwritten Offering of Common Stock
14. Juni 2024 08:03 ET
|
Disc Medicine Inc
WATERTOWN, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization...
Disc Medicine Presents Positive Clinical Data Across Portfolio at the European Hematology Association (EHA) 2024 Congress
14. Juni 2024 07:30 ET
|
Disc Medicine Inc
Updated analyses of data from AURORA and BEACON studies further demonstrate clinical activity of bitopertin across multiple measures of erythropoietic protoporphyria (EPP) and support development path...
Disc Medicine to Participate in the Jefferies Global Healthcare Conference
30. Mai 2024 09:00 ET
|
Disc Medicine Inc
WATERTOWN, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...
Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2024 Congress
14. Mai 2024 10:30 ET
|
Disc Medicine Inc
Additional analyses of data from AURORA, as well as the full adult data set from BEACONUpdated data from the ongoing Phase 1b study of DISC-0974 in myelofibrosis (MF) patients with anemia, including a...
Disc Medicine to Participate in the H.C. Wainwright BioConnect Investor Conference
13. Mai 2024 08:00 ET
|
Disc Medicine Inc
WATERTOWN, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...
Disc Medicine Reports First Quarter 2024 Financial Results and Provides Business Update
09. Mai 2024 08:00 ET
|
Disc Medicine Inc
Presented top-line results from AURORA, the placebo-controlled phase 2 study of bitopertin in erythropoietic porphyrias (EPP), in April 2024On track to deliver additional analyses from BEACON and...